The company also said all approvals are in place for fund infusion of Rs 4,000 crore from IHH Healthcare Berhad and the transaction will be completed shortly.
Consolidated income from operations of the company stood at Rs 1,139.90 crore for the quarter under consideration. It was Rs 1,197.17 crore for the same period a year ago.
In its update on transactions, the company also said about "fund infusion of Rs 4,000 crore with the preferential allotment to provide IHH with a 31 per cent stake followed by an open offer by IHH for up to 26 per cent of the expanded equity capital of the company", it added.
Capital raised would primarily be utilised to complete the proposed acquisition of RHT Indian assets which will result in elimination of clinical establishment fee that Fortis pays to RHT, the healthcare provider said.
Commenting on the results and deal, Fortis Healthcare Chairman Ravi Rajagopal said: "While this quarter has witnessed strong performance versus the trailing quarter, the impending investment by IHH would further help strengthen the business."
All approvals pertaining to the Fortis IHH transaction are now in place and both the organisation are working to complete the transaction expeditiously, he added.
The company had net debt of Rs 1,497 crore and a net debt to equity ratio of 0.29 times as on September 30, 2018, Fortis Healthcare said.
Shares of Fortis Healthcare Ltd today closed at Rs 140.10 per scrip on the BSE, up 0.94 per cent from their previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)